REG - Arecor Therapeutics - Expansion of specialty hospital collaboration

Arecor TherapeuticsAnnouncement

08/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240108:nRSH8679Ya&default-theme=true

RNS Number : 8679Y  Arecor Therapeutics PLC  08 January 2024

Arecor Therapeutics plc

("Arecor" or the "Group")

 

ARECOR ANNOUNCES EXPANSION OF EXISTING SPECIALTY HOSPITAL FORMULATION
COLLABORATION

 

Cambridge, UK, 8 January 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces the expansion of its ongoing, exclusive formulation study
collaboration with the pharmaceutical division of one of the world's largest
chemicals marketing and pharmaceuticals companies, which focuses on the
development and commercialisation of speciality drugs.

 

The collaboration, in which Arecor is using its proprietary formulation
technology platform, Arestat™, to develop a differentiated, ready-to-use
liquid formulation of its partner's product, AT351, has progressed
significantly since it began in November 2022. Arecor will now undertake
additional in-house activities to accelerate the development programme,
enabling rapid progress towards its partner's Pre-Investigational New Drug
(Pre-IND) meeting with the US FDA.

 

The partner will provide additional funds for Arecor's expanded development
work and continues to have an option to acquire the rights to the new
proprietary formulation and associated Intellectual Property under Arecor's
technology licensing model to further develop and commercialise the product.
 

 

Sarah Howell, Chief Executive Officer of Arecor, said: "The rapid progress of
this collaboration and expansion of the development project illustrate the
value that our proprietary technology platform, Arestat™, and our experience
in the specialty hospital field, can bring to our partners and the development
of differentiated medicines to improve patient outcomes."

 

This announcement contains inside information for the purposes of the
retained UK version of the EU Market Abuse Regulation (EU) 596/2014 ("UK
MAR").

 

-ENDS-

 

 

 

 

 

For more information, please contact:

 

 Arecor Therapeutics plc                          www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer         Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Susan Lowther, Chief Financial Officer           Tel: +44 (0) 1223 426060

                                                  Email: info@arecor.com

 Mo Noonan, Communications                        Tel: +44 (0) 7876 444977

                                                  Email: mo.noonan@arecor.com

 Panmure Gordon (UK) Limited (NOMAD and Broker)   Tel: +44 (0) 20 7886 2500

 Freddy Crossley, Emma Earl (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville      Tel: +44 (0) 20 3709 5700

                                                  Email: arecor@consilium-comms.com

 

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFETLRIDIIS